🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 15 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/06/1999 | 10,00 | 10,13 | 9,97 | 10,00 | -0,31% | 1,56% | 78.800 |
| 28/05/1999 | 9,89 | 10,03 | 9,88 | 10,03 | +0,94% | 1,58% | 443.400 |
| 27/05/1999 | 9,91 | 9,94 | 9,84 | 9,94 | +0,00% | 0,95% | 87.800 |
| 26/05/1999 | 9,98 | 10,06 | 9,78 | 9,94 | -0,63% | 2,82% | 460.000 |
| 25/05/1999 | 9,88 | 10,03 | 9,69 | 10,00 | +0,31% | 3,48% | 621.400 |
| 24/05/1999 | 10,06 | 10,19 | 9,88 | 9,97 | -1,54% | 3,11% | 449.200 |
| 21/05/1999 | 10,22 | 10,28 | 10,06 | 10,13 | -0,61% | 2,14% | 343.200 |
| 20/05/1999 | 10,31 | 10,38 | 10,19 | 10,19 | -2,40% | 1,82% | 203.400 |
| 19/05/1999 | 10,31 | 10,50 | 10,25 | 10,44 | +0,60% | 2,42% | 320.600 |
| 18/05/1999 | 10,44 | 10,50 | 10,25 | 10,38 | +1,22% | 2,40% | 132.400 |
| 17/05/1999 | 10,06 | 10,25 | 10,06 | 10,25 | +1,23% | 1,86% | 202.400 |
| 14/05/1999 | 10,31 | 10,38 | 10,03 | 10,13 | -1,82% | 3,33% | 222.200 |
| 13/05/1999 | 10,25 | 10,44 | 10,00 | 10,31 | +2,48% | 4,27% | 527.400 |
| 12/05/1999 | 10,31 | 10,31 | 10,00 | 10,06 | -2,13% | 3,03% | 147.400 |
| 11/05/1999 | 10,38 | 10,44 | 10,19 | 10,28 | -0,90% | 2,41% | 248.800 |
| 10/05/1999 | 10,31 | 10,47 | 10,25 | 10,38 | +0,91% | 2,12% | 358.600 |
| 07/05/1999 | 10,13 | 10,38 | 10,13 | 10,28 | -0,30% | 2,47% | 296.600 |
| 06/05/1999 | 10,25 | 10,34 | 10,13 | 10,31 | +0,00% | 2,13% | 94.400 |
| 05/05/1999 | 10,31 | 10,50 | 10,00 | 10,31 | -2,08% | 4,85% | 135.400 |
| 04/05/1999 | 10,44 | 10,63 | 10,31 | 10,53 | -0,30% | 2,99% | 98.600 |
| 03/05/1999 | 10,56 | 10,69 | 10,50 | 10,56 | +0,00% | 1,78% | 310.600 |
| 30/04/1999 | 10,50 | 10,66 | 10,31 | 10,56 | +1,20% | 3,27% | 497.600 |
| 29/04/1999 | 10,31 | 10,47 | 10,25 | 10,44 | +0,00% | 2,12% | 60.800 |
| 28/04/1999 | 10,63 | 10,63 | 10,25 | 10,44 | -1,76% | 3,53% | 139.000 |
| 27/04/1999 | 10,06 | 10,69 | 10,00 | 10,63 | +1,80% | 6,83% | 538.600 |
| 26/04/1999 | 10,34 | 10,88 | 10,28 | 10,44 | +0,00% | 5,74% | 210.600 |
| 23/04/1999 | 10,38 | 10,44 | 10,13 | 10,44 | -1,76% | 3,01% | 235.200 |
| 22/04/1999 | 11,50 | 11,50 | 10,19 | 10,63 | -7,10% | 11,41% | 1.242.000 |
| 21/04/1999 | 11,63 | 11,63 | 11,25 | 11,44 | -0,54% | 3,23% | 314.400 |
| 20/04/1999 | 11,25 | 11,66 | 11,06 | 11,50 | +1,80% | 5,28% | 301.400 |